Cargando…

Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel

BACKGROUND: Classic infantile onset of Pompe disease (c-IOPD) leads to hypotonia and hypertrophic cardiomyopathy within the first days to weeks of life and, without treatment, patients die of cardiorespiratory failure in their first 1–2 years of life. Enzymatic replacement therapy (ERT) with algluco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gragnaniello, Vincenza, Deodato, Federica, Gasperini, Serena, Donati, Maria Alice, Canessa, Clementina, Fecarotta, Simona, Pascarella, Antonia, Spadaro, Giuseppe, Concolino, Daniela, Burlina, Alberto, Parenti, Giancarlo, Strisciuglio, Pietro, Fiumara, Agata, Casa, Roberto Della
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898438/ https://www.ncbi.nlm.nih.gov/pubmed/35248118 http://dx.doi.org/10.1186/s13052-022-01219-4

Ejemplares similares

Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy
por: Parini, Rossella, et al.
Publicado: (2018)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease
por: Zhu, Diqi, et al.
Publicado: (2022)

Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
por: Beck, Michael
Publicado: (2009)

Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
por: Schoser, Benedikt
Publicado: (2013)

Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
por: Ertoy Karagol, Hacer Ilbilge, et al.
Publicado: (2023)

S2.2 Enzyme replacement therapy in the infantile-onset Pompe disease
por: Parenti, Giancarlo, et al.
Publicado: (2011)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting
por: Toscano, Antonio, et al.
Publicado: (2022)

Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency
por: Di Rocco, Maja, et al.
Publicado: (2023)

Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study
por: van Gelder, C. M., et al.
Publicado: (2016)

Unusual Evolution of Hypertrophic Cardiomyopathy in Non-Compaction Myocardium in a Pompe Disease Patient
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

S1.2 The pediatrician and the early onset Pompe disease
por: Fecarotta, Simona, et al.
Publicado: (2011)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy
por: Fecarotta, Simona, et al.
Publicado: (2013)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α
por: Kishnani, Priya, et al.
Publicado: (2017)

STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021)

Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement
por: Paoletti, Matteo, et al.
Publicado: (2020)

The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa
por: Baek, Rena C., et al.
Publicado: (2016)

Orofacial features and pediatric dentistry in the long-term management of Infantile Pompe Disease children
por: Galeotti, Angela, et al.
Publicado: (2020)

Double dose alglucosidase-alpha doubles benefit?
por: Finsterer, Josef, et al.
Publicado: (2018)

Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region
por: Al-Hassnan, Zuhair, et al.
Publicado: (2022)

New treatments for the mucopolysaccharidoses: from pathophysiology to therapy
por: Fecarotta, Simona, et al.
Publicado: (2018)

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Correction: Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region
por: Al-Hassnan, Zuhair, et al.
Publicado: (2023)

Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy
por: Brunetti-Pierri, Nicola, et al.
Publicado: (2020)

Congenital hyperinsulinism in clinical practice: From biochemical pathophysiology to new monitoring techniques
por: Martino, Mariangela, et al.
Publicado: (2022)

Quantitative analysis of upright standing in adults with late-onset Pompe disease
por: Valle, Maria Stella, et al.
Publicado: (2016)

The Outcome of Infantile Onset Pompe Disease in South of Iran
por: Moravej, Hossein, et al.
Publicado: (2016)

The infantile-onset form of Pompe disease: an autopsy diagnosis
por: dos Santos, Otávio César Cruz, et al.
Publicado: (2015)

Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy
por: Quan, Jun-Jun, et al.
Publicado: (2017)

Nystagmus in infantile Pompe disease: a new feature?
por: Turco, Emanuela Claudia, et al.
Publicado: (2020)

Incidence of infantile Pompe disease in the Maroon population of French Guiana
por: Elenga, Narcisse, et al.
Publicado: (2018)

Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
por: Fiumara, Agata, et al.
Publicado: (2023)

Cognitive outcome of classic infantile Pompe patients receiving enzyme therapy
por: Ebbink, BJ, et al.
Publicado: (2013)

Clinical laboratory experience of blood CRIM testing in infantile Pompe disease
por: Bali, Deeksha S., et al.
Publicado: (2015)

Effects of immunomodulation in classic infantile Pompe patients with high antibody titers
por: Poelman, E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_siqi3cp7sqvsqrm8sd6c4f352i